Samjin Pharmaceuticals Stock Forecast for 2023 - 2025 - 2030
Updated on 05/02/2024
Samjin Pharmaceuticals Fair Value Forecast for 2023 - 2025 - 2030
Samjin Pharmaceuticals's Price has decreased In the last year, from ₩6820.66 to ₩0.00 – a 100.00% drop. In the next year, analysts believe that Fair Value will reach ₩0.00 – an increase of 100.00%. For the next six years, the forecast is for Fair Value to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| A128940 Stock Forecast | Hanmi Pharm. | Outperform |
18
|
₩319.50k | Buy/Sell | ₩382.71k | 31.46% |
| A008930 Stock Forecast | Hanmi Science | - |
14
|
₩42.55k | Buy/Sell | ₩0.00 | -100.00% |
| A000250 Stock Forecast | Sam Chun Dang Pharm. | - |
6
|
₩112.50k | Buy/Sell | ₩80.00k | -100.00% |
| A145020 Stock Forecast | Hugel | Buy |
16
|
₩205.50k | Buy/Sell | ₩201.75k | 6.57% |
| A009420 Stock Forecast | Hanall Biopharma | Buy |
14
|
₩35.65k | Buy/Sell | ₩44.67k | 26.23% |
Samjin Pharmaceuticals Revenue Forecast for 2023 - 2025 - 2030
Samjin Pharmaceuticals's Revenue has seen impressive growth In the last year, rising from ₩250.07B to ₩274.03B – a growth of 9.58%. In the following year, 0 experts forecast Samjin Pharmaceuticals's Revenue will decrease by 8.74%, to ₩250.08B. In 2030, professionals predict that Samjin Pharmaceuticals's Revenue will decrease by 5.30%, to ₩259.51B.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| A019170 Stock Forecast | Shinpoong Pharmaceutical Co.,L... | - |
14
|
₩12.96k | Buy/Sell | ₩0.00 | -100.00% |
| A185750 Stock Forecast | Chong Kun Dang Pharmaceutical | Outperform |
16
|
₩103.50k | Buy/Sell | ₩124.29k | 44.93% |
| A069620 Stock Forecast | Daewoong pharmaceutical Co.,Lt... | Buy |
16
|
₩111.70k | Buy/Sell | ₩156.10k | 43.24% |
.jpg)
Samjin Pharmaceuticals Dividend per Share Forecast for 2023 - 2025 - 2030
In the last year, Samjin Pharmaceuticals's Dividend per Share has seen a drop from ₩800.00 to ₩800.00 – a 0.00% decrease. According to 0 major analysts, Samjin Pharmaceuticals's Dividend per Share will fall by 0.00% in the next year, reaching ₩800.00. Professionals believe that By 2030, Samjin Pharmaceuticals's Dividend per Share will fall to ₩800.00– a 0.00% decrease from its current value.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| A005250 Stock Forecast | Green Cross Holdings | - |
16
|
₩16.17k | Buy/Sell | ₩0.00 | -100.00% |
| A003090 Stock Forecast | Daewoong | Outperform |
14
|
₩19.03k | Buy/Sell | ₩38.00k | 31.37% |
| A003850 Stock Forecast | Boryung | Buy |
17
|
₩11.19k | Buy/Sell | ₩13.50k | 42.98% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| A086450 Stock Forecast | DongKook Pharmaceutical | Buy |
16
|
₩16.56k | Buy/Sell | ₩20.00k | 44.93% |
| A001060 Stock Forecast | JW Pharmaceutical | Buy |
14
|
₩30.80k | Buy/Sell | ₩40.62k | 36.36% |
| A000640 Stock Forecast | Dong-A Socio Holdings | - |
13
|
₩110.20k | Buy/Sell | ₩0.00 | -100.00% |
Samjin Pharmaceuticals EBITDA Forecast for 2023 - 2025 - 2030
In the last year, Samjin Pharmaceuticals's EBITDA has fallen from ₩41.27B to ₩33.00B – a 20.04% decrease. Analysts predict that Samjin Pharmaceuticals's EBITDA will increase in the upcoming year, reaching ₩41.27B. This would represent an increase of 25.06%. Over the next eight years, experts predict that Samjin Pharmaceuticals's EBITDA will grow at a rate of 18.65%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| A170900 Stock Forecast | Dong-A ST | Outperform |
17
|
₩68.10k | Buy/Sell | ₩74.50k | 19.68% |
| A058820 Stock Forecast | CMG Pharmaceutical | - |
14
|
₩2.24k | Buy/Sell | ₩0.00 | -100.00% |
| A140410 Stock Forecast | Mezzion Pharma | - |
6
|
₩36.55k | Buy/Sell | ₩0.00 | -100.00% |
Samjin Pharmaceuticals EBIT Forecast for 2023 - 2025 - 2030
In the last year, Samjin Pharmaceuticals's EBIT has decreased from ₩33.91B to ₩23.18B – a 31.63% drop. In the next year, analysts believe that EBIT will reach ₩33.91B – an increase of 46.27%. For the next eight years, the forecast is forEBIT to grow by 37.93%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| A102460 Stock Forecast | REYON Pharmaceutical | - |
15
|
₩15.75k | Buy/Sell | ₩0.00 | -100.00% |
| A047920 Stock Forecast | HLB Pharmaceutical | - |
4
|
₩32.40k | Buy/Sell | ₩0.00 | -100.00% |
| A003000 Stock Forecast | Bukwang Pharmaceutical | - |
10
|
₩6.38k | Buy/Sell | ₩17.66k | -100.00% |
Samjin Pharmaceuticals EPS Price Prediction Forecast for 2023 - 2025 - 2030
Samjin Pharmaceuticals's EPS has decreased In the last year, from ₩2266.00 to ₩0.00 – a 100.00% drop. In the next year, analysts believe that EPS will reach ₩0.00 – an increase of 100.00%. For the next six years, the forecast is for EPS to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| A249420 Stock Forecast | Ildong Pharmaceutical | Outperform |
12
|
₩15.56k | Buy/Sell | ₩23.00k | 60.67% |
| A053030 Stock Forecast | BINEX | - |
16
|
₩13.81k | Buy/Sell | ₩18.00k | -100.00% |
| A007570 Stock Forecast | Ilyang Pharmaceutical Co.,Ltd | - |
13
|
₩14.56k | Buy/Sell | ₩0.00 | -100.00% |
Site Navigation
.jpg)